Halozyme Therapeutics, Inc.
HALO
$38.97
$0.260.67%
| Weiss Ratings | HALO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Good | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | B | |||
| Rating Factors | HALO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Excellent | |||
| Efficiency Index | Excellent | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | HALO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.75 | |||
| Price History | HALO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -2.07% | |||
| 30-Day Total Return | -8.23% | |||
| 60-Day Total Return | 10.52% | |||
| 90-Day Total Return | -6.04% | |||
| Year to Date Total Return | 1.12% | |||
| 1-Year Total Return | 12.73% | |||
| 2-Year Total Return | -15.24% | |||
| 3-Year Total Return | -25.07% | |||
| 5-Year Total Return | 130.55% | |||
| 52-Week High % Change | -13.98% | |||
| 52-Week Low % Change | 29.68% | |||
| Price | HALO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $45.00 | |||
| 52-Week Low Price | $29.85 | |||
| 52-Week Low Price (Date) | May 09, 2023 | |||
| 52-Week High Price (Date) | Aug 10, 2023 | |||
| Valuation | HALO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 4.91B | |||
| Enterprise Value | 6.10B | |||
| Price/Earnings (TTM) | 18.28 | |||
| Earnings Per Share (TTM) | 2.11 | |||
| Earnings Per Share Growth | 45.50% | |||
| Price/Earnings To Growth | 0.40 | |||
| Price/Sales (TTM) | 6.11 | |||
| Price/Book (Q) | 58.45 | |||
| Enterprise Value/Revenue (TTM) | 7.37 | |||
| Price | $37.81 | |||
| Enterprise Value/EBITDA (TTM) | 14.58 | |||
| Enterprise Value/EBIT | 17.85 | |||
| Market Cap Category | Mid Cap | |||
| Dividends and Shares | HALO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 131.04M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | HALO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 858 794 8889 | |||
| Address | 12390 El Camino Real San Diego, CA 92130 | |||
| Website | halozyme.com | |||
| Country | United States | |||
| Year Founded | 1998 | |||
| Profitability | HALO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 41.31% | |||
| Profit Margin | 33.95% | |||
| Management Effectiveness | HALO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 11.98% | |||
| Return on Equity | 222.07% | |||
| Income Statement | HALO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 829.25M | |||
| Total Revenue (TTM) | 829.25M | |||
| Revenue Per Share | $6.33 | |||
| Gross Profit (TTM) | 560.53M | |||
| EBITDA (TTM) | 419.43M | |||
| EBIT (TTM) | 342.57M | |||
| Net Income (TTM) | 281.59M | |||
| Net Income Avl. to Common (TTM) | 281.59M | |||
| Total Revenue Growth (Q YOY) | 26.75% | |||
| Earnings Growth (Q YOY) | 47.98% | |||
| EPS Diluted (TTM) | 2.11 | |||
| EPS Diluted Growth (Q YOY) | 54.62% | |||
| Balance Sheet | HALO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 336.00M | |||
| Cash Per Share (Q) | $2.56 | |||
| Total Current Assets (Q) | 746.42M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 83.81M | |||
| Current Ratio (Q) | 6.635 | |||
| Book Value Per Share (Q) | $0.66 | |||
| Total Assets (Q) | 1.73B | |||
| Total Current Liabilities (Q) | 112.49M | |||
| Total Debt (Q) | 1.53B | |||
| Total Liabilities (Q) | 1.65B | |||
| Total Common Equity (Q) | 83.81M | |||
| Cash Flow | HALO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -96.91M | |||
| Cash from Financing (TTM) | -407.99M | |||
| Net Change in Cash (TTM) | -116.33M | |||
| Levered Free Cash Flow (TTM) | 271.98M | |||
| Cash from Operations (TTM) | 388.57M | |||
